Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CytoDyn Inc CYDY

Healthcare Biotechnology
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Its core areas of clinical development are human immunodeficiency viruses (HIV), non-alcoholic steatohepatitis (NASH), and solid tumors in oncology. The areas of clinical focus in HIV are the lifting of the clinical hold, creation of a long-acting formulation of leronlimab and an HIV functional cure in using adenovirus vectors (AAV). In NASH, its focus is on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Regarding oncology, its focus remains on combination therapy for solid tumors.


OTCQB:CYDY - Post by User

CytoDyn Inc
Bullboard Posts
User Avatar Image
(1)
•••
Post by sunny3999on May 16, 2020 5:03pm
153 Views
Post# 31038471

COVID-19 Research Symposium vom May 19-21 with Dr. Patterson

COVID-19 Research Symposium vom May 19-21 with Dr. Patterson
Bruce Patterson, M.D.
Disruption of the CCL5/RANTES-CCR5 Pathway 1 Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19
CEO, IncellDx, California, USA
12:00 - 12:30 pm (US EDT)
 
https://pages.beckman.com/fmna-liqh-covid19-symposium-20-04-wbn-usa_00-lp-register8.html
 
Join the leading industry experts as we navigate through research trials, workflows, and best practices to overcome the COVID-19 pandemic.
 
Each day will highlight a new topic with new speakers sharing their expertise on the following:
- May 19: Understanding the Immune Response
- May 20: Viral Particle Detection & Characterization
- May 21: Vaccine & Therapy Development
 
Register today for the whole event or select sessions. SEATS ARE LIMITED for this high demand special event.
Zeit
19.May.2020 11:00 AM
20.May.2020 11:00 AM
21.May.2020 11:00 AM
 Eastern Time (USA und Kanada)
User image
 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities